BTIG analyst Julian Harrison has maintained their neutral stance on UTHR stock, giving a Hold rating yesterday.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Julian Harrison has given his Hold rating due to a combination of factors that balance near‑term pressure with longer‑term optionality. United Therapeutics again fell short of quarterly revenue expectations, largely because Tyvaso sales lagged consensus, while Yutrepia’s rapid uptake heightens concern about future share erosion in the core Tyvaso pulmonary hypertension franchise.
At the same time, Harrison sees meaningful potential offsets from clinical and pipeline catalysts, including strong TETON‑2 data in IPF, upcoming TETON‑1 results, and the impending readout from the ADVANCED OUTCOMES study with ralinepag. Management’s plan to launch the new soft‑mist inhaler Tresmi and the company’s sizable cash balance add strategic flexibility, but unresolved patent litigation and competitive uncertainty keep the risk‑reward profile balanced rather than compelling, supporting a Hold stance.
Harrison covers the Healthcare sector, focusing on stocks such as Apogee Therapeutics, Nektar Therapeutics, and Ardelyx. According to TipRanks, Harrison has an average return of 37.7% and a 55.37% success rate on recommended stocks.
In another report released yesterday, Bank of America Securities also reiterated a Hold rating on the stock with a $569.00 price target.